



## Research article

Borderline resistance to oxacillin in *Staphylococcus aureus* after treatment with sub-lethal sodium hypochlorite concentrations

Stephanie Speck<sup>a,\*</sup>, Cindy Wenke<sup>a</sup>, Andrea T. Feßler<sup>b</sup>, Johannes Kacza<sup>c</sup>, Franziska Geber<sup>a</sup>, Anissa D. Scholtzek<sup>b</sup>, Dennis Hanke<sup>b</sup>, Inga Eichhorn<sup>b</sup>, Stefan Schwarz<sup>b</sup>, Maciej Rosolowski<sup>d</sup>, Uwe Truyen<sup>a</sup>

<sup>a</sup> Institute of Animal Hygiene and Veterinary Public Health, University of Leipzig, Leipzig, Germany

<sup>b</sup> Institute of Microbiology and Epizootics, Centre of Infection Medicine, Department of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany

<sup>c</sup> BioImaging Core Facility, VMF/SIKT, University of Leipzig, Leipzig, Germany

<sup>d</sup> Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany

## ARTICLE INFO

## Keywords:

Microbiology  
Antibiotic resistant bacteria  
Antimicrobial  
Bacteriology  
Health sciences  
*Staphylococcus*  
Veterinary medicine  
*Staphylococcus aureus*  
Sodium hypochlorite  
Cell wall  
Transmission electron microscopy  
BORSA  
GdpP

## ABSTRACT

Surface disinfectants are regularly used in prophylactic and infection control measures. Concern has been raised whether residues of sub-inhibitory disinfectant concentrations may constitute a selective pressure and could contribute to the development of strains which are tolerant and/or resistant to biocides including antibiotics. The current study investigated whether *Staphylococcus* (*S.*) *aureus* ATCC® 29213™ and ATCC® 6538™ would change their growth characteristics and antimicrobial susceptibility profiles after prolonged treatment with sub-inhibitory concentrations of sodium hypochlorite (NaOCl). NaOCl is a fast-acting disinfectant with a broad-spectrum activity, inexpensive and widely used in healthcare and the food production industry. Minimum inhibitory concentration (MIC) for NaOCl was determined by broth macrodilution according to the guidelines for disinfectant efficacy testing provided by the German Veterinary Medical Society. Serial passages after 24 h and 72 h, respectively, in defined sub-inhibitory concentrations of NaOCl resulted in a number of phenotypic variants. Two of these variants, derived from *S. aureus* ATCC® 29213™, showed elevated MICs of oxacillin and were considered as *in vitro*-generated borderline oxacillin-resistant *S. aureus* (BORSA). Transmission electron microscopy revealed a significantly thickened cell wall in these isolates, a phenomenon that has also been described for *Listeria monocytogenes* after low-level exposure to NaOCl. Whole genome sequencing revealed an early stop codon in the gene coding for the GdpP protein and thereby abolishing the function of this gene. GdpP represents a phosphodiesterase that regulates gene expression, and loss of function of the GdpP protein has been described in association with borderline oxacillin resistance. Our findings suggest that a mutation in the GdpP protein gene and morphological changes of the cell wall were induced by repeated exposure to sub-lethal NaOCl concentrations, and most likely accounted for a BORSA phenotype in two variants derived from *S. aureus* ATCC® 29213™.

## 1. Introduction

Exposure to low-level concentrations of biocides may trigger bacterial adaptive responses or resistance against antimicrobial agents *in vitro* (Thomas et al., 2000; Chapman, 2003; Karatzas et al., 2007; Randall et al., 2007; Meyer and Cookson, 2010). This has been studied extensively for triclosan, quaternary ammonium compounds, and chlorhexidine (reviewed in Kampf, 2018). Furthermore, antibacterial biocides at low concentrations induce horizontal gene transfer, thereby facilitating the spread of antimicrobial resistance genes between bacteria *in vitro*

(Jutkina et al., 2018; Kampf, 2018). Inappropriate use of surface disinfectants (for example, incorrect concentration or excessive sub-inhibitory biocide residues on surfaces) may constitute a selective pressure contributing to the development of tolerant or resistant strains (Li et al., 1997; Russell, 2001, 2004; Huet et al., 2008). Sodium hypochlorite (NaOCl) is a strong oxidizing agent with a broad-spectrum antimicrobial efficacy against a wide range of bacteria, including multidrug-resistant bacteria (Köhler et al., 2018). NaOCl is available worldwide, is favorable in terms of cost and benefit and is used for a wide range of applications, for example disinfection of surfaces, laundry, and drinking water

\* Corresponding author.

E-mail address: [stephanie@speck-kaysser.de](mailto:stephanie@speck-kaysser.de) (S. Speck).

<https://doi.org/10.1016/j.heliyon.2020.e04070>

Received 10 December 2019; Received in revised form 21 January 2020; Accepted 21 May 2020

2405-8440/© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

(Rutala and Weber, 1997; Anonymous, 2013; Pereira et al., 2015). In the European Economic Area/and or Switzerland, it is approved for use as a biocide for human hygiene, disinfection, veterinary hygiene, food and animal feeds, and drinking water (<https://echa.europa.eu/de/substance-information/-/substanceinfo/100.028.790>). Likely concentrations at which NaOCl (calculated as available chlorine) will be used as a product-type 3 for veterinary hygiene vary between 2,000 mg/L (0.2%) and 30,000 mg/L (3%) (Anonymous, 2017). Resistance to NaOCl is very uncommon (reviewed in Kampf, 2018). Despite this, a minimum inhibitory concentration (MIC) of 4,100 mg/L active chlorine (*Salmonella* spp., *Staphylococcus* (*S.*) *aureus*) and 8,200 mg/L (*Enterococcus* spp., *Escherichia coli*, *Klebsiella pneumoniae*) was proposed to determine resistance (reviewed in Kampf, 2018).

*S. aureus* is an important pathogen in human and veterinary medicine, livestock production, and food processing. *S. aureus* is tolerant to desiccation and survives for months on dry surfaces (Kramer et al., 2006; Kadariya et al., 2014). Only few studies exist regarding effects observed after low-level exposure of *S. aureus* to NaOCl (Kusumaningrum et al., 2003; Buzón-Durán et al., 2017; Ujimine et al., 2017). Recently, biofilm production by methicillin-resistant *S. aureus* (MRSA) induced by sub-inhibitory concentrations of NaOCl has been demonstrated (Buzón-Durán et al., 2017). The present study investigated whether repeated treatment of *S. aureus* by sub-inhibitory concentrations of NaOCl would have an effect on antimicrobial susceptibility, growth characteristics on sheep blood agar, and susceptibility to NaOCl.

## 2. Materials and methods

### 2.1. Bacterial strains and growth conditions

Experiments were conducted using *S. aureus* (SA) strains ATCC® 29213™ and ATCC® 6538™. Strain ATCC® 29213™ is the well characterized quality control strain for antimicrobial susceptibility testing (AST) (MIC determination and disk diffusion) recommended by EUCAST (Anonymous, 2019). According to ATCC® strain characteristics, it is susceptible to oxacillin ([https://www.lgcstandards-atcc.org/products/all/29213.aspx?geo\\_country=de#characteristics](https://www.lgcstandards-atcc.org/products/all/29213.aspx?geo_country=de#characteristics)) and exhibits weak  $\beta$ -lactamase activity (Anonymous, 2019). *S. aureus* ATCC® 6538™ is a control strain according to DIN 58959-9 (Anonymous, 1997) and the reference strain for disinfectant efficacy testing (Anonymous, 2019a). Both strains were obtained from the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures (DSMZ; Braunschweig, Germany). Cultures were grown overnight on Columbia sheep blood agar (CSA) containing 7% blood (Oxoid Deutschland GmbH/Thermo Scientific, Wesel, Germany) at 37 °C. AST was performed at a DIN EN ISO 15189 accredited diagnostic laboratory (amedes MVZ für Laboratoriumsdiagnostik und Mikrobiologie Halle/Leipzig GmbH, Halle, Germany) using VITEK®2 technology (bioMérieux Deutschland GmbH, Nürtingen, Germany) according to the EUCAST recommendations. Results were evaluated using clinical breakpoints given by EUCAST ([http://www.eucast.org/clinical\\_breakpoints/](http://www.eucast.org/clinical_breakpoints/)).

### 2.2. Determination of minimum inhibitory concentrations for NaOCl

MIC values for NaOCl were determined following the “Guidelines for disinfectant testing”, provided by the German Veterinary Medical Society (DVG e.V.) (Anonymous, 2019a). The final concentrations tested were 0.01% (v/v), 0.02%, 0.03% and so on up to 0.1%, 0.25% and 0.5% NaOCl (CAS-No. 7681-52-9; AppliChem GmbH, Darmstadt, Germany; 10%–14% active chlorine according to the manufacturer). Each concentration was tested in duplicate at two independent occasions. In brief, screw cap tubes containing 2.5 mL double concentrated tryptic soy broth (TSB) were filled up with 2.5 mL of double concentrated NaOCl. Subsequently, 50  $\mu$ L of *S. aureus* ( $1.4$ – $1.9 \times 10^9$  colony-forming units (cfu)/mL)

were added to each test tube. Preparations were mixed and incubated at 37 °C. After 72 h of incubation, turbidity was measured as an indicator of bacterial growth. The lowest concentration with absence of growth was interpreted as MIC.

### 2.3. Effect of sub-inhibitory NaOCl concentrations on growth characteristics, susceptibility to NaOCl, and antimicrobial susceptibility

The following sub-inhibitory concentrations of NaOCl were arbitrarily defined: 0.01%, 0.005%, 0.0025%, 0.00125%, 0.0006%, and 0.0003%. Experiments were performed according to Karatzas et al. (2007), but modified in that we chose two different contact times, i.e. 24 h and 72 h. The latter incubation time corresponded to NaOCl MIC determination. Tubes were prepared and incubated at 37 °C as described above. The initial inoculum for both strains was  $8.5 \times 10^8$  cfu/mL. From all tubes showing bacterial growth after the respective contact time, a 50  $\mu$ L-aliquot was transferred to a freshly prepared tube containing the same NaOCl concentration and further incubated (Figure 1). This was repeated eight times after 24 h and twice after 72 h of incubation. From all tubes showing bacterial growth at the end of each experiment, aliquots were spread out on CSA using a 1  $\mu$ L disposable loop. After 24 h of incubation at 37 °C, colony morphology was noted and colonies of different phenotype were separated on new CSA plates. Each of these isolates was subjected to NaOCl MIC determination (Figure 1) and AST (amedes MVZ für Laboratoriumsdiagnostik und Mikrobiologie Halle/Leipzig GmbH) as described above. AST was further performed after two subcultures on CSA. In addition, NaOCl MIC was determined after two serial passages in TSB. Both were intended to test whether any observed changes in the susceptibility patterns was robust. All isolates were stored at -80 °C for further investigation (CRYOBANK™ tubes; MAST Diagnostika GmbH, Reinfeld, Germany). As a control, the experiments using strains ATCC® 29213™ and ATCC® 6538™ as described above were additionally performed using TSB without any supplementation.

### 2.4. Macrorestriction analysis

Macrorestriction analysis was performed using the original *S. aureus* ATCC® 29213™ and two variant isolates (SA29213-A, SA29213-B) with altered phenotypes to confirm the clonal identity. *Sma*I and *Apa*I were used as restriction enzymes as described elsewhere (Murchan et al., 2003; Kadlec et al., 2009).

### 2.5. Agar disk diffusion


In addition, agar disk diffusion was performed using penicillin (10 U, Oxoid Deutschland GmbH/Thermo Scientific) according to CLSI standards for *S. aureus* ATCC® 29213™ and the two strains SA29213-A and SA29213-B (CLSI, 2019). The zone edges of the penicillin inhibition zones were evaluated according to the zone edge test (CLSI, 2019).

### 2.6. $\beta$ -lactam susceptibility testing by broth microdilution

Additional broth microdilution was performed for *S. aureus* ATCC® 29213™ as well as its variants SA29213-A and SA29213-B according to CLSI standards (CLSI, 2019) using ampicillin, amoxicillin/clavulanic acid, penicillin, ceftiofur, cefquinome, cephalothin, cefazolin, cefotaxime, cefoperazone, and oxacillin.

### 2.7. Growth kinetics of *S. aureus* ATCC® 29213™ and its variants

A propagation assay was used to evaluate possible changes in the fitness of SA29213-A and SA29213-B compared to *S. aureus* ATCC® 29213™. Bacteria were grown from cryo-stocks on CSA at 37 °C for 24 h. A fresh overnight subculture (CSA, 37 °C) was used to perform growth



**Figure 1.** Schematic presentation of the experimental setup. Both *S. aureus* ATCC® strains were inoculated into tryptic soy broth (TSB) containing different concentrations of NaOCl. Turbidity after the respective incubation time indicated bacterial growth. From turbid cultures, a 50 µL-aliquot was transferred to a freshly prepared tube containing the same NaOCl concentration and further incubated. This was repeated eight times after 24 h and twice after 72 h of incubation, respectively. At the end of each experiment, subcultures were prepared on CSA, colony morphology was noted and colonies of different phenotype were further investigated. x% indicates a NaOCl concentration of 0.01%, 0.005%, 0.0025%, 0.00125%, 0.0006%, and 0.0003%, respectively.

kinetics. Cells were suspended in TSB resulting in an initial inoculum of  $5.5 \times 10^8$  cfu/mL (*S. aureus* ATCC® 29213™),  $5.8 \times 10^8$  cfu/mL (SA29213-A), and  $6.1 \times 10^8$  cfu/mL (SA29213-B), respectively. Each suspension was used to inoculate 24 wells (100 µL/well) on a 96-well flat-bottom microtiter plate (Sarstedt AG & Co., Nümbrecht, Germany). The remaining wells were filled with TSB only and served as blank. The plate was incubated over a period of 6 h at 37 °C without shaking. Bacterial growth was measured every 15 min by recording the optical density at 595 nm using a Multiskan Ascent (Thermo LabSystems, Helsinki, Finland) microplate reader. Prior to recording, the plate was shaken for 3 s at 480 rpm. The assay was performed twice.

## 2.8. Transmission electron microscopy (TEM)

*S. aureus* ATCC®29213™, SA29213-A, and SA29213-B were grown at 37 °C overnight in TSB. Thereafter, cultures were centrifuged at 300 x g for 15 min and the supernatants were discarded. A total of 2.5 mL of glutaraldehyde (2.5% in 0.1 M sodium cacodylate buffer with 0.1 M sucrose, 1 mM CaCl<sub>2</sub>, pH 7.2) was added to the bacterial cell pellet, gently mixed and incubated for 1 h at room temperature. Thereafter, a 1.2 mL-aliquot of each preparation was transferred to a tube, and centrifuged (500 x g, 15 min) again. Supernatants were removed, pellets rinsed in phosphate-buffered saline (PBS; pH 7.4) at room temperature for 10 min. Centrifugation, removal of supernatants and rinsing in PBS two times for 10 min was repeated twice for each bacterial isolate. Prior to secondary fixation and embedding in resin 10 µL of each glutaraldehyde-fixed bacterial cell pellet were injected into a LUMI-Tainer™ microcapsule (diameter 3.5 mm) (LUM GmbH, Berlin, Germany) for easier handling. Further processing for secondary fixation and embedding was conducted as follows: osmification with 1% OsO<sub>4</sub> (in 0.1 M cacodylate buffer with 1.5% potassium hexacyanoferrate (II) trihydrate; Sigma-Aldrich, St. Louis MO, USA) for 2 h, rinsing in distilled water (five times for 7 min each), dehydration in ascending methanol including propylene oxide as intermedium (twice for 10 min each), and

resin embedding in glycid ether 100™ (Serva, Heidelberg, Germany). Ultra-thin sections (50 nm) were cut and collected on uncoated 300 mesh nickel thin bar grids.

Thirty cells of each preparation with nearly equatorial cut surfaces were chosen to determine cell wall thickness. Digital TEM images were taken at a final magnification of  $\times 20,000$  using a Zeiss EFTEM Libra 120™ (Zeiss, Oberkochen, Germany) and were analyzed with the TEM-based image analysis software (iTEM). For each cell, measurements were performed at five cell wall positions by two investigators, independently. To evaluate differences in cell wall thickness between the three strains, a linear mixed effects model was fitted to the data. The strain and an indicator of the person who took the measurements were treated as fixed covariates, and the model included random intercept for each cell. The model allowed for evaluator-specific variance of the random intercepts. The model was compared to other candidate models using likelihood ratio tests. The goodness of fit of the model was assessed by inspection of its residuals. Results are expressed as means  $\pm$  standard deviation (SD). P-values were computed using the fitted model, treating the parental strain as a reference. Differences were regarded as significant for  $P < 0.05$ . Analyses were performed using R, version 3.4.1 (R Core Team, 2019). Mixed effects models were fitted using the R package nlme.

## 2.9. Whole genome sequencing and sequence analysis

*S. aureus* ATCC® 29213™ as well as its variants SA29213-A and SA29213-B were subjected to whole genome sequencing (WGS). For DNA extraction the QIAamp® DNA Mini Kit (QIAGEN, Hilden, Germany) was used with some modifications. To lyse the staphylococcal cell wall, 25 µL lysostaphin solution (0.1 mg/mL) was added to the cells prior to incubation for 25 min at 37 °C. After this, 75 µL TE buffer and 25 µL proteinase K (0.1 mg/L) were added and incubation continued for 25 min at 37 °C. 75 µL PBS and 2 µL RNase (2 µg/µL) were added and slightly mixed. Then the protocol for the kit was followed starting with the addition of AL buffer. The Nextera XT library preparation kit (Illumina

Inc., San Diego, USA) was used for the preparation of the WGS libraries according to the manufacturer's recommendations. The 2×300 bp paired-end sequencing in 40-fold multiplexes was performed on the Illumina MiSeq (Illumina Inc., San Diego, USA) platform. SPAdes 3.14.0 (Nurk et al., 2013) was used for *de novo* assembly of the raw reads. The sequence of *S. aureus* ATCC® 29213™ was used as reference to which the variants SA29213-A and SA29213-B were mapped with Bowtie2 (Langmead and Salzberg, 2012). The obtained sequences were annotated using RAST annotation server (Aziz et al., 2008) and compared to each other and with *S. aureus* ATCC® 29213™ reference (NZ\_LHUS00000000). The nucleotide sequences were analyzed using Geneious v 11.1.4 (Biomatters, Auckland, New Zealand). Regarding the reduced oxacillin susceptibility, the sequences of the three strains in question were compared for the proteins GdpP, FemA, FemB, MgrA, MprF (using *S. aureus* NCTC 8325 (NCBI:txid93061) as a reference) and FemC (GlnR), FemD (GlmM), CcpA as well as the penicillin binding proteins (PBP) 1, 2, 3 and 4 (using *S. aureus* Mu50 (NCBI:txid158878) as a reference). Regarding the phenotypic differences in the hemolysis patterns of the three strains, sequences of the three strains in question were compared for the proteins of the bicomponent gamma-hemolysins (HlgA, HlgB and HlgC) (using *S. aureus* Mu50 (NCBI:txid158878) as a reference) as well as alpha-hemolysin (Hla) and delta-hemolysin (Hld) (using *S. aureus* NCTC8325 (NCBI:txid93061) as a reference).

### 3. Results

#### 3.1. Phenotypic characteristics of *S. aureus* ATCC®29213™ and ATCC® 6538™

On CSA, *S. aureus* ATCC®29213™ grew in medium-sized, smooth, golden-yellow colonies with a narrow zone of complete hemolysis (Figure 2 A) and was susceptible to all antimicrobial agents tested except benzylpenicillin (Table 1). The MIC value determined for NaOCl was 0.07%. *S. aureus* ATCC®6538™ revealed medium-sized, smooth, golden-yellow colonies with a clear zone of complete hemolysis. The strain was susceptible to all antimicrobial agents tested (Table 1) and exhibited a NaOCl MIC value of 0.1%.

#### 3.2. Effect of sub-inhibitory concentrations of NaOCl on growth characteristics, susceptibility to NaOCl, and antimicrobial susceptibility

In experiments with serial passages after 24 h of incubation, growth of *S. aureus* ATCC® 29213™ occurred at 0.0003%, 0.0006%, 0.00125%, and 0.0025%. In contrast, growth also occurred in 0.005% NaOCl in experiments with serial passages after 72 h of incubation. Changes in colony morphology were visible in both experimental setups. Besides typical *S. aureus* ATCC® 29213™ colonies, eight different phenotypes with and without hemolysis were found (Table 2). Antimicrobial susceptibility profiles of all strains were identical except for oxacillin, levofloxacin, fosfomycin, and linezolid (Table 1). Strains SA29213-A (Figure 2 B) and SA29213-B (Figure 2 C) exhibited decreased susceptibility to oxacillin (MIC ≥4 mg/L) with an at least 16-fold increase in the MIC values compared to *S. aureus* ATCC® 29213™ (Table 1). Two


subcultures on CSA were performed to prove whether these changes were reversible. MICs decreased to 2 mg/L (i.e. susceptible) after the first subculture but were consistent with the first result (i.e. resistant, ≥4 mg/L oxacillin) after the second subculture on CSA. The MICs determined for NaOCl ranged from 0.07% to 0.09% (Table 2). The agar disk diffusion test for *S. aureus* ATCC® 29213™, SA29213-A, and SA29213-B revealed a zone diameter of 20 mm for penicillin (Figure 3 A–C). Thus, all three strains were classified as penicillin resistant (CLSI, 2019). The corresponding zone edges were sharp, which indicated the presence of a β-lactamase (CLSI, 2019). Broth microdilution also confirmed that the original strain and the two variants were resistant to penicillin. The MICs of the two variants were 2 mg/L compared to 1 mg/L for the original strain. However, it should be noted that deviations of +/- one dilution step are within the acceptable range for AST (CLSI, 2018a). The oxacillin MIC of the original strain was 0.25 mg/L compared with 1 mg/L for both variants. This corresponded to an increase of the MIC by two dilution steps, although the variants would still be considered as susceptible (CLSI, 2019). A slight increase in the MICs was also seen for ampicillin, amoxicillin/clavulanic acid, ceftiofur, cephalothin, cefazolin, cefotaxime and cefoperazone, whereas no change was seen among the MICs for cefquinome (Supplementary Table 1). Growth curves of *S. aureus* ATCC® 29213™ and its two variants are shown in Figure 4. After a short lag phase, a distinct increase in cell density corresponding to an increase in optical density was noticed for *S. aureus* ATCC® 29213™. In contrast, growth of SA29213-A and SA29213-B seemed to be impaired as demonstrated by a less steep growth curve and lower cell densities. Figure 4 summarizes average values obtained from two independent growth experiments.

*S. aureus* ATCC® 6538™ grew at concentrations up to 0.01% NaOCl in both experimental setups. Colony morphology also varied (Table 2), but the antimicrobial susceptibility profiles of the four derived variants (Table 1) closely resembled that of the original strain *S. aureus* ATCC® 6538™. MICs for NaOCl were identical to the values determined initially (0.1 mg/L) with the exception of SA6538-c and SA6538-d. For both, the MIC was 2.5-times higher, but decreased to 0.1% after one passage in TSB (Table 2).

Control experiments performed in TSB did not result in changes of colony morphology for both *S. aureus* strains, ATCC® 29213™ and ATCC® 6538™. The antimicrobial susceptibility profiles revealed a slight increase in MICs e.g. for levofloxacin or erythromycin (Supplementary Table 2), but overall strains showed resistance patterns identical to the original strains. The MIC determined for NaOCl at the end of the experiments was 0.05% and 0.06%. Detailed results can be taken from Supplementary Table 2.

#### 3.3. Macrorestriction analysis

Macrorestriction analysis using *Sma*I and *Apa*I revealed indistinguishable pulsed-field gel electrophoresis (PFGE) patterns for *S. aureus* ATCC® 29213™ and variants SA29213-A and SA29213-B (Figure 5, Supplementary Figure 1 and Supplementary Figure 2).



**Figure 2.** A–C. Colony appearance of *S. aureus* grown on Columbia sheep blood agar for 24 h at 37°C. (A) Parental strain ATCC® 29213™. (B) Variant SA29213-A obtained after serial passages in 0.005% NaOCl. (C) Variant SA29213-B obtained after serial passages in 0.005% NaOCl.

**Table 1.** MIC values of both ATCC® *S. aureus* strains and their variants obtained by Vitek®2 analysis.

Antibiotic substance	Minimum inhibitory concentrations (mg/L)													
	<i>S. aureus</i> strains and variants													
	ATCC® 29213™	SA29213-A	SA29213-B	SA29213-C	SA29213-D	SA29213-E	SA29213-F	SA29213-G	SA29213-H	ATCC® 6538™	SA6538-a	SA6538-b	SA6538-c	SA6538-d
Benzylpenicillin	≥0.5 <sup>b</sup>	≥0.5 <sup>b</sup>	≥0.5 <sup>b</sup>	0.25 <sup>b</sup>	≥0.5 <sup>b</sup>	≥0.5 <sup>b</sup>	≥0.5 <sup>b</sup>	≥0.5 <sup>b</sup>	≥0.5 <sup>b</sup>	≤0.03 <sup>a</sup>	0.06 <sup>a</sup>	≤0.03 <sup>a</sup>	≤0.03 <sup>a</sup>	≤0.03 <sup>a</sup>
Oxacillin	≤0.25 <sup>a</sup>	≥4 <sup>b,*</sup>	≥4 <sup>b,*</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	0.5 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	0.5 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>
Gentamicin	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>
Levofloxacin	0.25 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	0.25 <sup>a</sup>	0.5 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	0.25 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>
Erythromycin	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>
Clindamycin	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>	≤0.25 <sup>a</sup>
Vancomycin	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	1 <sup>a</sup>	1 <sup>a</sup>	≤0.5 <sup>a</sup>	1 <sup>a</sup>
Teicoplanin	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>
Tetracycline	≤1.0 <sup>a</sup>	≤1.0 <sup>a</sup>	≤1.0 <sup>a</sup>	≤1.0 <sup>a</sup>	≤1.0 <sup>a</sup>	≤1.0 <sup>a</sup>	≤1.0 <sup>a</sup>	≤1.0 <sup>a</sup>	≤1.0 <sup>a</sup>	≤1.0 <sup>a</sup>	≤1.0 <sup>a</sup>	≤1.0 <sup>a</sup>	≤1.0 <sup>a</sup>	≤1.0 <sup>a</sup>
Tigecycline	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>	≤0.12 <sup>a</sup>
Rifampicin	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>
Fosfomycin	≤8 <sup>a</sup>	16 <sup>a</sup>	≤8 <sup>a</sup>	≤8 <sup>a</sup>	≤8 <sup>a</sup>	≤8 <sup>a</sup>	≤8 <sup>a</sup>	≤8 <sup>a</sup>	≤8 <sup>a</sup>	≤8 <sup>a</sup>	≤8 <sup>a</sup>	≤8 <sup>a</sup>	≤8 <sup>a</sup>	≤8 <sup>a</sup>
Fusidic acid	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>	≤0.5 <sup>a</sup>
Mupirocin	≤2 <sup>a</sup>	≤2 <sup>a</sup>	≤2 <sup>a</sup>	≤2 <sup>a</sup>	≤2 <sup>a</sup>	≤2 <sup>a</sup>	≤2 <sup>a</sup>	≤2 <sup>a</sup>	≤2 <sup>a</sup>	≤2 <sup>a</sup>	≤2 <sup>a</sup>	≤2 <sup>a</sup>	≤2 <sup>a</sup>	≤2 <sup>a</sup>
Linezolid	2 <sup>a</sup>	1 <sup>a</sup>	1 <sup>a</sup>	2 <sup>a</sup>	2 <sup>a</sup>	2 <sup>a</sup>	2 <sup>a</sup>	1 <sup>a</sup>	2 <sup>a</sup>	2 <sup>a</sup>	2 <sup>a</sup>	1 <sup>a</sup>	2 <sup>a</sup>	2 <sup>a</sup>

\*Both isolates were repeatedly tested and results for oxacillin varied between 2 mg/L (i.e. interpreted as susceptible) and ≥4 mg/L (i.e. interpreted as resistant).


<sup>a</sup> Values interpreted as susceptible.

<sup>b</sup> Values interpreted as resistant.

**Table 2.** Phenotypic characteristics of *S. aureus*-derived variants obtained after serial passages in sub-inhibitory NaOCl concentrations.

Strain	NaOCl concentration (v/v)	Serial passage after	Colony morphology on CSA	Variant	MIC value for NaOCl determined after		
					culture on CSA	1 <sup>st</sup> passage in TSB	2 <sup>nd</sup> passage in TSB
ATCC® 29213™	0.005%	72 h	tiny, yellow, narrow hemolysis	SA29213-A	0.08%	0.07%	0.07%
	0.005%	72 h	tiny, yellow, very narrow hemolysis	SA29213-B	0.08%	0.07%	0.07%
	0.005%	72 h	medium-sized, lutescent, narrow hemolysis	SA29213-F	0.08%	0.09%	0.08%
	0.0025%	72 h	small, lutescent, no hemolysis	SA29213-E	0.08%	0.08%	0.07%
	0.0006%	72 h	convex, yellow, distinct hemolysis	SA29213-C	0.08%	0.08%	0.07%
	0.0025%	24 h	medium-sized, yellow, narrow hemolysis	SA29213-H	0.08%	0.07%	0.07%
	0.0025%	24 h	medium-sized, yellow, no hemolysis	SA29213-D	0.08%	0.08%	0.08%
	0.00125%	24 h	small, yellow, weak hemolysis beneath the colony	SA29213-G	0.07%	0.07%	0.09%
ATCC® 6538™	0.01%	24 h	tiny, yellowish, no hemolysis	SA6538-a	0.1%	not done	not done
	0.005%	24 h	small, yellow, no hemolysis	SA6538-b	0.1%	not done	not done
	0.01%	72 h	small, convex, yellow, no hemolysis	SA6538-c	0.25%	0.1%	not done
	0.0025%	72 h	small, convex, yellowish, distinct hemolysis	SA6538-d	0.25%	0.1%	not done


At the end of each experiment (i.e. eight times serial subculture after 24 h and two serial subcultures after 72 h of incubation, respectively) subcultures were prepared on CSA from every tube showing bacterial growth. Cultures were grown at 37 °C for 24 h and colony morphology was assessed thereafter. Each colony with a different phenotype was separated on CSA. CSA – Columbia sheep blood agar (7% blood), NaOCl – sodium hypochlorite, MIC – minimum inhibitory concentration, TSB – tryptic soy broth.

**Figure 3.** A-C. Results of the penicillin disk diffusion test. A – *S. aureus* ATCC® 29213™; B – variant SA29213-A; C – variant SA29213-B.

### 3.4. Transmission electron microscopy

Morphological changes in *S. aureus* SA29213-A and SA29213-B were examined by TEM and compared to *S. aureus* ATCC® 29213™. TEM micrographs of representative cells are shown in Figure 6 A-C. The mean

cell wall thickness of *S. aureus* ATCC® 29213™ was 18.96 nm (95% CI: 17.70–20.22). SA29213-A and SA29213-B exhibited a significantly thickened cell wall phenotype of 26.30 nm (95% CI: 25.04–27.56,  $P = 1.89 \times 10^{-12}$ ) and 21.11 nm (95% CI: 19.85–22.37,  $P = 0.018$ ), respectively.



**Figure 4.** Growth of *S. aureus* ATCC® 29213™ (filled circles), SA29213-A (filled triangles), and SA29213-B (open boxes) monitored by determining the optical densities at 595 nm in TSB at 37 °C without shaking. Experiments were performed in duplicate and error bars represent the standard deviation.

### 3.5. Sequence analysis


The analysis of the proteins associated with reduced oxacillin susceptibility revealed no differences in the amino acid (aa) sequences of FemA, FemB, FemC, FemD, MgrA, CcpA and MprF as well as the penicillin binding proteins (PBP) 1, 2, 3 and 4. However, compared to the original strain *S. aureus* ATCC® 29213™, both variants, SA29213-A (bioproject PRJNA613990, acc. no. JAAVNA000000000) and SA29213-B (bioproject PRJNA613990, acc. no. JAAVMZ000000000), exhibited a change from Glutamin (Q) to a stop codon at position 139 in the 656 aa GdpP protein. Regarding the hemolysin proteins HlgA, HlgB, HlgC, Hla and Hld, no aa sequence differences between the original strain and the two variants were observed.

## 4. Discussion

*S. aureus* is an important opportunistic pathogen in humans, companion animals, and livestock. It survives on inanimate dry surfaces for months (Kramer et al., 2006), which highlights the necessity of proper surface disinfection measures. Exposure of bacteria to low concentrations of a disinfectant (e.g. inappropriate dilution, remnants of the disinfectant) might rapidly select for decreased susceptibility against this biocide or even to antibiotics (Loughlin et al., 2002; Thomas et al., 2005; SCENIHR, 2010). It has been demonstrated *in vitro* that a sub-lethal (often sub-inhibitory) biocide concentration decreases bacterial susceptibility to that biocide and modifies the antimicrobial susceptibility profile, but does not necessarily trigger clinical antimicrobial resistance (SCENIHR, 2009; SCENIHR, 2010).


In this study, the effect of sub-inhibitory concentrations of NaOCl on growth characteristics, susceptibility to NaOCl and antibiotic susceptibility patterns of two *S. aureus* strains was examined. Prolonged treatment with sub-inhibitory concentrations resulted in the development of colonies with noticeable differences in phenotype in that some colonies were smaller, discolored, and with impaired hemolysis. The characteristic color of *S. aureus* is mediated by carotenoids which are rapidly destroyed by NaOCl (Marshall and Wilmoth, 1981; Siems et al., 1999) resulting in chromogenic variants. Moreover, NaOCl stress has been associated with degradation of chromosomal DNA, alteration of proteins and disruption of the cell membrane (Aboualizadeh et al., 2017; Ujimine et al., 2017). It could be assumed that NaOCl-induced degradation of

chromosomal DNA may be related to the morphological changes described here. There was no change in MICs to NaOCl in NaOCl-adapted strains except for two variants obtained from *S. aureus* ATCC® 6538™ (i.e. SA6538-c and SA6538-d). Both strains showed a 2.5-times decrease in susceptibility to NaOCl but this was reversible by one passage in TSB, suggesting a temporary and not genetically fixed adaptation process. Similar findings have been reported elsewhere (Bansal et al., 2018; Gao and Liu, 2014). Treatment of bacteria with sub-inhibitory concentrations of NaOCl might contribute to the emergence of antibiotic resistance (Molina-González et al., 2014; Obe et al., 2018). This is supported by our findings in that two phenotypic variants of *S. aureus* ATCC® 29213™, i.e. SA29213-A and SA29213-B, showed *in vitro* borderline-resistance against oxacillin (MIC of  $\geq 4$  mg/L and 2 mg/L). In accordance to others (Molina-González et al., 2014) this phenomenon was strain-dependent as it was not seen in isolates derived from *S. aureus* strain ATCC® 6538™. It should briefly be mentioned that MIC values for oxacillin determined by VITEK®2 technology distinctly varied from those determined by broth microdilution (Supplementary Table 1). This might be associated with the different testing methods used and has been previously described (Scholtzek et al., 2019). Macrorestriction analysis excluded a laboratory contamination with another *S. aureus* strain and confirmed the clonality of SA29213-A, SA29213-B, and *S. aureus* ATCC® 29213™. Borderline-resistant *S. aureus* (BORSA) are characterized by oxacillin MICs at or just above the susceptibility breakpoint (Chambers, 1997). Several mechanisms have been hypothesized to explain borderline resistance in *mecA*-negative *S. aureus*, including hyperproduction of a  $\beta$ -lactamase, amino acid substitutions in penicillin-binding proteins (PBPs), or mutations in regulating genes that lead to PBP4 overproduction (McDougal and Thornsberry, 1986; Tomasz et al., 1989; Argudín et al., 2018). Recently, plasmid-encoded methicillin resistance conferred by *mecB* has also been described in *S. aureus* (Becker et al., 2018). *S. aureus* ATCC® 29213™ is characterized as oxacillin-susceptible and exhibits oxacillin MICs ranging between 0.12 – 0.5 mg/L (CLSI, 2018b). Furthermore, a GenBank database search found no entries for methicillin-resistance genes in *S. aureus* ATCC® 29213™. Therefore, these genetically determined resistance mechanisms could be excluded in our strains. Another mechanism causing reduced susceptibility to oxacillin is the upregulation of multiple-drug efflux pumps as described for *S. aureus* after multiple-exposure to benzalkonium chloride (Huet et al., 2008). Unfortunately, this aspect could not further be investigated



**Figure 5.** *SmaI* and *ApaI* fragment patterns obtained after PFGE analysis. M – *SmaI*-digested *S. aureus* strain NCTC 8325, pt – *S. aureus* ATCC® 29213™, A – variant SA29213-A, B – variant SA29213-B. The full, non-adjusted PFGE images of *SmaI*- and *ApaI*-digestions can be found as [Supplementary Figure 1](#) (*SmaI*) and [Supplementary Figure 2](#) (*ApaI*). Figure 5 was composed of the five lanes taken from the middle part of each gel image.

in our study. Borderline oxacillin resistance can be attributed to  $\beta$ -lactamase hyperproduction (McDougal and Thornsberry, 1986; Maalej et al., 2012; Hryniewicz and Garbacz, 2017; Scholtzek et al., 2019). *S. aureus* ATCC® 29213™ possesses the *blaZ* gene (GenBank accession number NZ\_MOPB01000048) which encodes a penicillin-hydrolyzing class A  $\beta$ -lactamase. Penicillin agar disk diffusion with the interpretation of the zone edges confirmed the presence and the expression of a  $\beta$ -lactamase, not only in *S. aureus* ATCC® 29213™, but also in the two derived isolates tested. Interestingly, no differences in the zone diameters were seen between *S. aureus* ATCC® 29213™, SA29213-A and SA29213-B. Therefore, the expression of the  $\beta$ -lactamase is unlikely to be the reason of the reduced oxacillin susceptibility. As  $\beta$ -lactam antimicrobials interfere with bacterial cell wall synthesis, the decreased susceptibility to oxacillin of SA29213-A and SA29213-B might be associated with substantial reorganization of the staphylococcal cell wall, which was significantly thicker in the two variants as compared to *S. aureus* ATCC® 29213™. Heterogeneity of the cell wall thickness after NaOCl treatment was also found in TEM observations by Ujimine et al. (2017). Moreover, the decreased oxacillin susceptibility might also be associated with the mutation resulting in an early stop codon in the gene coding for the GdpP protein and thereby abolishing the function of this gene. GdpP represents a phosphodiesterase that regulates gene expression, and loss of function of the GdpP protein has been described in association with borderline oxacillin resistance (Griffiths and O'Neill, 2012). This protein comprises two functional domains: The GGDEF domain containing a diguanylate cyclase, which confers the capacity to synthesize the second nucleotide messenger cyclic di-GMP. The DHH domain harbors the phosphodiesterase characteristic catalytic DHH motif and imparts hydrolysis of cyclic di-AMP, a second messenger molecule which is involved in cell wall synthesis and homeostasis, and is essential for the growth and cell viability of many Gram-positive bacteria including *S. aureus* (Corrigan et al., 2011; Huynh and Woodward, 2016; Fahmi et al., 2017; Commichau et al., 2018). Impaired growth was also seen in both variants of *S. aureus* ATCC® 29213™. Cell wall changes after low-level exposure to NaOCl were also described for *Listeria monocytogenes*, another Gram-positive bacterial species (Gao and Liu, 2014; Bansal et al., 2018). Similar morphological and biological changes, including decreased growth rate, less or no hemolysis, have been described for vancomycin- and teicoplanin-resistant *S. aureus*, adaptive resistance to amikacin, and treatment of *S. aureus* with erythromycin and acriflavine (Nishino, 1975; Cui et al., 2003; McCallum et al., 2006; Kawai et al., 2009; Dai et al., 2012; Yuan et al., 2013). Our findings may suggest that a mutation in the gene for the GdpP protein and morphological changes of the cell wall induced by NaOCl most likely accounted for a borderline oxacillin resistance phenotype in the two *S. aureus* ATCC® 29213™ variants. Survival of such variant strains in certain environmental niches may constitute a possible threat to susceptible populations, particularly in healthcare.



**Figure 6.** A-C. Comparison of cell wall thickness of SA29213-A and SA29213-B with the parental strain *S. aureus* ATCC® 29213™. Thin-section micrographs of the following strains are shown: A – *S. aureus* ATCC® 29213™; B – variant SA29213-A; C – variant SA29213-B. Final magnification  $\times 20,000$ . Scale bar indicates 200 nm.

## Declarations

### Author contribution statement

Stephanie Speck, Cindy Wenke, Andrea T. Feßler, Johannes Kacza, Anissa D. Scholtzek: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Franziska Geber: Performed the experiments; Analyzed and interpreted the data.

Dennis Hanke, Inga Eichhorn: Performed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Stefan Schwarz, Uwe Truyen: Conceived and designed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Maciej Rosolowski: Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

### Funding statement

This work was supported by the Saxon State Ministry of Social Affairs and Consumer Protection.

### Competing interest statement

The authors declare no conflict of interest.

### Additional information

Supplementary content related to this article has been published online at <https://doi.org/10.1016/j.heliyon.2020.e04070>.

### Acknowledgements

The authors are thankful to Mario Reinhardt, Dana Rüster, Christina Speck and Vivian Hensel for their help in the laboratory and for preparing figures. We acknowledge support from the German Research Foundation (DFG) and Leipzig University within the program of Open Access Publishing.

### References

- Aboualizadeh, E., Bumah, V.V., Masson-Meyers, D.S., Eells, J.T., Hirschmugl, C.J., Enwemeka, C.S., 2017. Understanding the antimicrobial activity of selected disinfectants against methicillin-resistant *Staphylococcus aureus* (MRSA). *PLoS One* 12 (10), e0186375.
- Anonymous, Deutsches Institut für Normung e.V., N. M., 1997. DIN 58959-9 Anforderungen an den Einsatz von Kontrollstämmen zur Prüfung von Kulturmedien mit Beiblatt 1. Beuth Verlag.
- Anonymous, DIN EN 901:2013-12, 2013. Chemicals Used for Treatment of Water Intended for Human Consumption - Sodium Hypochlorite. German version.
- Anonymous, 2017. Regulation (EU) No 528/2012 Concerning the Making Available on the Market and Use of Biocidal Products. Active Chlorine Released from Sodium Hypochlorite Product-type 3 (Veterinary hygiene). January 2017. Available from: <https://echa.europa.eu/documents/10162/cd256d88-480e-3ff8-5aea-8d658d6e24a9> Cited 10 April 2020.
- Anonymous, The European Committee on Antimicrobial Susceptibility Testing, 2019. Routine and Extended Internal Quality Control for MIC Determination and Disk Diffusion as Recommended by EUCAST. Version 9.0, 2019. Available from: <http://www.eucast.org>. Cited 23 April 2019.
- Anonymous, 2019a. DVG Guidelines for MIC. Available from: [http://www.desinfektion-dvg.de/fileadmin/FG\\_Desinfektion/Dokumente/Fuer\\_Gutachter/Pruefrichtlinien/IV\\_MHK\\_7Nov20175.pdf](http://www.desinfektion-dvg.de/fileadmin/FG_Desinfektion/Dokumente/Fuer_Gutachter/Pruefrichtlinien/IV_MHK_7Nov20175.pdf) Cited. (Accessed 23 April 2019).
- Argudín, M.A., Roisin, S., Nienhaus, L., Dodémont, M., de Mendonça, R., Nonhoff, C., et al., 2018. Genetic diversity among *Staphylococcus aureus* isolates showing oxacillin and/or cefoxitin resistance not linked to the presence of *mec* genes. *Antimicrob. Agents Chemother.* 62 (7) e00091-18.
- Aziz, R.K., Bartels, D., Best, A.A., DeJongh, M., Disz, T., Edwards, R.A., et al., 2008. The RAST Server: rapid annotations using subsystems technology. *BMC Genom.* 9, 75.
- Bansal, M., Nannapaneni, R., Sharma, C.S., Kiess, A., 2018. *Listeria monocytogenes* response to sublethal chlorine induced oxidative stress on homologous and heterologous stress adaptation. *Front. Microbiol.* 9, 2050.

- Becker, K., van Alen, S., Idelevich, E.A., Schleimer, N., Seggewiß, J., Mellmann, A., et al., 2018. Plasmid-encoded transferable *mecB*-mediated methicillin resistance in *Staphylococcus aureus*. *Emerg. Infect. Dis.* 24 (2), 242–248.
- Buzón-Durán, L., Alonso-Calleja, C., Riesco-Peláez, F., Capita, R., 2017. Effect of sub-inhibitory concentrations of biocides on the architecture and viability of MRSA biofilms. *Food Microbiol.* 65, 294–301.
- Chambers, H.F., 1997. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. *Clin. Microbiol. Rev.* 10 (4), 781–791.
- Chapman, J.S., 2003. Disinfectant resistance mechanisms, cross-resistance, and co-resistance. *Int. Biodeterior. Biodegrad.* 51, 271–276.
- CLSI, 2019. Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100, 29th ed. vol 39. Clinical and Laboratory Standards Institute, Wayne, PA, USA.
- CLSI, 2018a. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. In: CLSI Standard VET01, fifth ed. Clinical and Laboratory Standards Institute, Wayne, PA, USA.
- CLSI, 2018b. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. In: CLSI Supplement VET08, fourth ed. Clinical and Laboratory Standards Institute, Wayne, PA, USA.
- Commichau, F.M., Heidemann, J.L., Ficner, R., Stülke, J., 2018. Making and breaking of an essential poison: the cyclases and phosphodiesterases that produce and degrade the essential second messenger cyclic di-AMP in bacteria. *J. Bacteriol.* 201 e00462-18.
- Corrigan, R.M., Abbott, J.C., Burhenne, H., Kaever, V., Gründling, A., 2011. c-di-AMP is a new second messenger in *Staphylococcus aureus* with a role in controlling cell size and envelope stress. *PLoS Pathog.* 7 (9), e1002217.
- Cui, L., Ma, X., Sato, K., Okuma, K., Tenover, F.C., Mamizuka, E.M., et al., 2003. Cell wall thickening is a common feature of vancomycin resistance in *Staphylococcus aureus*. *J. Clin. Microbiol.* 41 (1), 5–14.
- Dai, Y., Zhou, X., Ma, X., Lu, H., Li, H., 2012. Misidentification of vancomycin-resistant *Staphylococcus aureus* as coagulase-negative *Staphylococcus*. *J. Med. Microbiol.* 61 (10), 1454–1458.
- Fahmi, T., Port, G.C., Cho, K.H., 2017. c-di-AMP: an essential molecule in the signaling pathways that regulate the viability and virulence of Gram-positive bacteria. *Genes (Basel)* 8 (8), E197.
- Gao, H., Liu, C., 2014. Biochemical and morphological alteration of *Listeria monocytogenes* under environmental stress caused by chloramine-T and sodium hypochlorite. *Food Contr.* 46, 455–461.
- Griffiths, J.M., O'Neill, A.J., 2012. Loss of function of the GdpP protein leads to joint  $\beta$ -lactam/glycopeptide tolerance in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 56, 579–581.
- Huet, A.A., Raygada, J.L., Mendiratta, K., Seo, S.M., Kaatz, G.W., 2008. Multidrug efflux pump overexpression in *Staphylococcus aureus* after single and multiple *in vitro* exposures to biocides and dyes. *Microbiology* 154 (Pt 10), 3144–3153.
- Huynh, T.N., Woodward, J.J., 2016. Too much of a good thing: regulated depletion of c-di-AMP in the bacterial cytoplasm. *Curr. Opin. Microbiol.* 30, 22–29.
- Hryniewicz, M.M., Garbacz, K., 2017. Borderline oxacillin-resistant *Staphylococcus aureus* (BORSA - A more common problem than expected? *J. Med. Microbiol.* 66, 1367–1373.
- Jutkina, J., Marathe, N.P., Flach, C.F., Larsson, D.G.J., 2018. Antibiotics and common antibacterial biocides stimulate horizontal transfer of resistance at low concentrations. *Sci. Total Environ.* 616–617, 172–178.
- Kadariya, J., Smith, T.C., Thapaliya, D., 2014. *Staphylococcus aureus* and staphylococcal food-borne disease: an ongoing challenge in public health. *BioMed Res. Int.* 2014, 827965.
- Kadlec, K., Ehrlich, R., Monecke, S., Steinacker, U., Kaspar, H., Mankertz, J., et al., 2009. Diversity of antimicrobial resistance phenotypes and genotypes of methicillin-resistant *Staphylococcus aureus* ST398 from diseased swine. *J. Antimicrob. Chemother.* 64 (6), 1156–1164.
- Kampf, G., 2018. Antiseptic Stewardship. Springer Nature Switzerland AG, Cham, Switzerland, p. 694.
- Karatzas, K.A., Webber, M.A., Jorgensen, F., Woodward, M.J., Piddock, L.J., Humphrey, T.J., 2007. Prolonged treatment of *Salmonella enterica* serovar Typhimurium with commercial disinfectants selects for multiple antibiotic resistance, increased efflux and reduced invasiveness. *J. Antimicrob. Chemother.* 60 (5), 947–955.
- Kawai, M., Yamada, S., Ishidoshiro, A., Oyama, Y., Ito, H., Yamagishi, J., 2009. Cell-wall thickness: possible mechanism of acriflavine resistance in methicillin-resistant *Staphylococcus aureus*. *J. Med. Microbiol.* 58 (Pt 3), 331–336.
- Köhler, A.T., Rodloff, A.C., Labahn, M., Reinhardt, M., Truyen, U., Speck, S., 2018 Nov. Efficacy of sodium hypochlorite against multidrug-resistant Gram-negative bacteria. *J. Hosp. Infect.* 100 (3), e40–e46.
- Kramer, A., Schwebke, I., Kampf, G., 2006. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. *BMC Infect. Dis.* 6, 130.
- Kusumaningrum, H.D., Paltinaite, R., Koomen, A.J., Hazeleger, W.C., Rombouts, F.M., Beumer, R.R., 2003. Tolerance of *Salmonella* Enteritidis and *Staphylococcus aureus* to surface cleaning and household bleach. *J. Food Protect.* 66 (12), 2289–2295.
- Li, X.-Z., Nikaido, H., Williams, K.E., 1997. Silver-resistant mutants of *Escherichia coli* display active efflux of Ag<sup>+</sup> and are deficient in porins. *J. Bacteriol.* 179, 6127–6132.
- Langmead, B., Salzberg, S.L., 2012. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* 9 (4), 357–359.
- Loughlin, M.F., Jones, M.V., Lambert, P.A., 2002. *Pseudomonas aeruginosa* cells adapted to benzalkonium chloride show resistance to other membrane-active agents but not to clinically relevant antibiotics. *J. Antimicrob. Chemother.* 49 (4), 631–639.



- Maalej, S.M., Rhimi, F.M., Fines, M., Mnif, B., Leclercq, R., Hammami, A., 2012. Analysis of borderline oxacillin-resistant *Staphylococcus aureus* (BORSA) strains isolated in Tunisia. *J. Clin. Microbiol.* 50 (10), 3345–3348.
- Marshall, J.H., Wilmoth, G.J., 1981 Sep. Pigments of *Staphylococcus aureus*, a series of triterpenoid carotenoids. *J. Bacteriol.* 147 (3), 900–913.
- McCallum, N., Karazum, H., Getzmann, R., Bischoff, M., Majcherzyk, P., Berger-Bächi, B., et al., 2006. In vivo survival of teicoplanin-resistant *Staphylococcus aureus* and fitness cost of teicoplanin resistance. *Antimicrob. Agents Chemother.* 50 (7), 2352–2360.
- McDougal, L.K., Thornsberry, C., 1986. The role of beta-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins. *J. Clin. Microbiol.* 23 (5), 832–839.
- Meyer, B., Cookson, B., 2010. Does microbial resistance or adaptation to biocides create a hazard in infection prevention and control? *J. Hosp. Infect.* 76 (3), 200–205.
- Molina-González, D., Alonso-Calleja, C., Alonso-Hernando, A., Capita, R., 2014. Effect of sub-lethal concentrations of biocides on the susceptibility to antibiotics of multi-drug resistant *Salmonella enterica* strains. *Food Contr.* 40, 329–334.
- Murchan, S., Kaufmann, M.E., Deplano, A., de Ryck, R., Struelens, M., Elsberg Zinn, C., et al., 2003. Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant *Staphylococcus aureus*: a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains. *J. Clin. Microbiol.* 41 (4), 1574–1585.
- Nishino, T., 1975. An electron microscopic study of antagonism between cephalixin and erythromycin in *Staphylococcus aureus*. *Jpn. J. Microbiol.* 19, 53–63.
- Nurk, S., Bankevich, A., Antipov, D., Gurevich, A., Korobeynikov, A., Lapidus, A., et al., 2013. Assembling genomes and mini-metagenomes from highly 800 chimeric reads. *J. Comput. Biol.* 20, 714–737.
- Obe, T., Nannapaneni, R., Sharma, C.S., Kiess, A., 2018. Homologous stress adaptation, antibiotic resistance, and biofilm forming ability of *Salmonella enterica* serovar Heidelberg ATCC8326 on different food-contact surfaces following exposure to sublethal chlorine concentrations. *Poultry Sci.* 97 (3), 951–961.
- Pereira, S.S., Oliveira, H.M., Turrini, R.N., Lacerda, R.A., 2015. Disinfection with sodium hypochlorite in hospital environmental surfaces in the reduction of contamination and infection prevention: a systematic review. *Rev. Esc. Enferm. USP* 49 (4), 681–688.
- Randall, L.P., Cooles, S.W., Coldham, N.G., Penuela, E.G., Mott, A.C., Woodward, M.J., et al., 2007. Commonly used farm disinfectants can select for mutant *Salmonella enterica* serovar Typhimurium with decreased susceptibility to biocides and antibiotics without compromising virulence. *J. Antimicrob. Chemother.* 60 (6), 1273–1280.
- R Core Team, 2019. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: <https://www.R-project.org>. Cited 11 June 2019.
- Russell, A.D., 2001. Mechanisms of bacterial insusceptibility to biocides. *Am. J. Infect. Contr.* 29, 259–261.
- Russell, A.D., 2004. Bacterial adaptation and resistance to antiseptics, disinfectants and preservatives is not a new phenomenon. *J. Hosp. Infect.* 57 (2), 97–104.
- Rutala, W.A., Weber, D.J., 1997. Uses of inorganic hypochlorite (bleach) in health-care facilities. *Clin. Microbiol. Rev.* 10 (4), 597–610.
- SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks), 19 January 2009. Assessment of the Antibiotic Resistance Effects of Biocides. Available from: [http://ec.europa.eu/health/ph\\_risk/committees/04\\_scenihp/docs/scenihp\\_o\\_021.pdf](http://ec.europa.eu/health/ph_risk/committees/04_scenihp/docs/scenihp_o_021.pdf). Cited 13 May 2019.
- SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks), 17 March 2010. Research Strategy to Address the Knowledge Gaps on the Antimicrobial Resistance Effects of Biocides. Available from: [http://ec.europa.eu/health/scientific\\_committees/emerging/docs/scenihp\\_o\\_028.pdf](http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihp_o_028.pdf). Cited 13 May 2019.
- Scholtzek, A.D., Hanke, D., Walther, B., Eichhorn, I., Stöckle, S.D., Klein, K.S., et al., 2019. Molecular characterization of equine *Staphylococcus aureus* isolates exhibiting reduced oxacillin susceptibility. *Toxins (Basel)* 11 (9), E535.
- Siems, W.G., Sommerburg, O., van Kuijk, F.J., 1999. Lycopene and beta-carotene decompose more rapidly than lutein and zeaxanthin upon exposure to various pro-oxidants in vitro. *Biofactors* 10 (2-3), 105–113.
- Thomas, L., Maillard, J.Y., Lambert, R.J., Russell, A.D., 2000. Development of resistance to chlorhexidine diacetate in *Pseudomonas aeruginosa* and the effect of a "residual" concentration. *J. Hosp. Infect.* 46 (4), 297–303.
- Thomas, L., Russell, A.D., Maillard, J.Y., 2005. Antimicrobial activity of chlorhexidine diacetate and benzalkonium chloride against *Pseudomonas aeruginosa* and its response to biocide residues. *J. Appl. Microbiol.* 98 (3), 533–543.
- Tomasz, A., Drugeon, H.B., de Lencastre, H.M., Jabes, D., McDougall, L., Bille, J., 1989. New mechanism for methicillin resistance in *Staphylococcus aureus*: clinical isolates that lack the PBP 2a gene and contain normal penicillin-binding proteins with modified penicillin-binding capacity. *Antimicrob. Agents Chemother.* 33 (11), 1869–1874.
- Ujjimine, S., Tone, S., Saito, M., Yamada, S., 2017. Intracellular morphological changes in *Staphylococcus aureus* induced by treatment with sodium hypochlorite. *Med. Mol. Morphol.* 50 (3), 178–184.
- Yuan, W., Hu, Q., Cheng, H., Shang, W., Liu, N., Hua, Z., et al., 2013. Cell wall thickening is associated with adaptive resistance to amikacin in methicillin-resistant *Staphylococcus aureus* clinical isolates. *J. Antimicrob. Chemother.* 68 (5), 1089–1096.